prikaz prve stranice dokumenta Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
No public access
Scientific paper - Original scientific paper
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
Journal of Child and Adolescent Psychopharmacology, 29 (2019), 3; 197-204. https://doi.org/10.1089/cap.2018.0044
Petrić, Daniela; Rački, Valentino; Gačo, Nadija; Kaštelan, Ana; Graovac, Mirjana

Cite this document

Petrić, D., Rački, V., Gačo, N., Kaštelan, A. & Graovac, M. (2019). Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology, 29. (3), 197-204. doi: 10.1089/cap.2018.0044

Petrić, Daniela, et al. "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients." Journal of Child and Adolescent Psychopharmacology, vol. 29, no. 3, 2019, pp. 197-204. https://doi.org/10.1089/cap.2018.0044

Petrić, Daniela, Valentino Rački, Nadija Gačo, Ana Kaštelan and Mirjana Graovac. "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients." Journal of Child and Adolescent Psychopharmacology 29, no. 3 (2019): 197-204. https://doi.org/10.1089/cap.2018.0044

Petrić, D., et al. (2019) 'Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients', Journal of Child and Adolescent Psychopharmacology, 29(3), pp. 197-204. doi: 10.1089/cap.2018.0044

Petrić D, Rački V, Gačo N, Kaštelan A, Graovac M. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients. Journal of Child and Adolescent Psychopharmacology [Internet]. 2019 [cited 2024 December 23];29(3):197-204. doi: 10.1089/cap.2018.0044

D. Petrić, V. Rački, N. Gačo, A. Kaštelan and M. Graovac, "Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients", Journal of Child and Adolescent Psychopharmacology, vol. 29, no. 3, pp. 197-204, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:454838. [Accessed: 23 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
AuthorDaniela Petrić
AuthorValentino Rački
AuthorNadija Gačo
AuthorAna Kaštelan
AuthorMirjana Graovac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Physiology, Immunology and Pathophxsiology)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Psychiatry and Psychological Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVE: The aim of this study was to explore the effectiveness and tolerability of long- acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone. METHODS: This study is a retrospective, noninterventional study to assess the effectiveness and tolerability of long-acting injectable antipsychotic paliperidone palmitate in first-episode adolescent patients during the first 12 months of treatment compared with the oral antipsychotic risperidone. The data include general sociodemographic characteristics, number of hospitalizations, side effects, and the following clinical scales: Positive and Negative Syndrome Scale (PANSS), Personal and Social Performance Scale (PSP), Clinical Global Impression Improvement and Severity (CGI-I and CGI-S), and Treatment Satisfaction Questionnaire for Medication (TSQM). RESULTS: During the 12- month study period significant improvement was registered in patients receiving both paliperidone palmitate and risperidone in the following scales: PANSS, PSP, CGI-I, and CGI-S. Patients receiving paliperidone palmitate had significantly greater improvement in PANSS, CGI- S, and PSP compared with the risperidone group. Patients receiving risperidone had significantly higher number of hospitalizations than the patients receiving paliperidone palmitate. The TSQM revealed that the patients who were receiving paliperidone palmitate achieved significantly higher scores on the convenience scale, global satisfaction, and on the overall result, whereas no difference was observed on the effectiveness scale. There were several side effects reported for paliperidone (5.5% hyperprolactinemia, 5.5% weight gain) and risperidone (5.5% hyperprolactinemia, 16.7% weight gain). CONCLUSIONS: In conclusion, paliperidone palmitate seems to be safe and effective in adolescent patients. Furthermore, it compared favorably with risperidone in the clinical response, side effects, and hospitalizations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Child and Adolescent Psychopharmacology
Numberingvol. 29, no. 3, pp. 197-204
p-ISSN1044-5463
DOIhttps://doi.org/10.1089/cap.2018.0044
URN:NBNurn:nbn:hr:184:454838
Publication2019
Document URLhttp://bib.irb.hr/1000322
Type of resourceText
Access conditionsClosed access
Terms of useLicence In copyright icon
Created on2022-03-08 12:27:00